Luzitin SA is a pharmaceutical development company focused on the pursuit of innovative solutions for photodynamic therapy (PDT). Luzitin’s mission is to investigate and develop innovative photosensitizing compounds for the treatment of cancer and other diseases, thus contributing to human wellness.

Luzitin offers access to a game changing and highly efficacious new molecular entity which will bring photodynamic therapy (PDT) into routine daily practice for the targeted therapy of solid tumors. Its technology consists of a combination of a proprietary new generation photosensitizer (Redaporfin) with a specific infrared-laser medical device.

One pager